Literature DB >> 25203451

Cytokines and mucosal immunity.

Giorgos Bamias1, Kristen O Arseneau, Fabio Cominelli.   

Abstract

PURPOSE OF REVIEW: Cytokines are integral mediators for maintaining intestinal mucosal homeostasis, as well as prominent effector molecules during chronic gut inflammatory diseases. This review focuses on recent studies of the role of specific cytokines in mucosal immunity. RECENT
FINDINGS: Dichotomous, or even opposing, functions have been described for several cytokines involved in intestinal innate immunity (most notably for members of the interleukin-1 family), which depend on the specific inflammatory conditions within the intestinal mucosa. For example, both interleukin-1α and interleukin-33 exhibit 'alarmin'-type properties that can signal tissue or cell damage, which further add to their well described proinflammatory roles. Costimulatory molecules of the tumor necrosis factor/tumor necrosis factor receptor superfamily, such as TNF-like cytokine 1A and LIGHT, are actively involved in mucosal proinflammatory pathways, but also may exert protection against infectious agents to facilitate recovery from acute inflammation. Finally, innate lymphoid cells are increasingly recognized as important cellular sources of pivotal mucosal cytokines, including the interleukin-23/T helper 17 cytokine, interleukin-22.
SUMMARY: Elucidating the complexity of cytokine signaling within the normal mucosa and during acute and chronic inflammation will be a pivotal step toward understanding the pathogenesis of immune-mediated gut diseases and developing effective therapies to treat them.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25203451      PMCID: PMC4234041          DOI: 10.1097/MOG.0000000000000118

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  46 in total

Review 1.  Immunopathogenesis of inflammatory bowel disease: current concepts.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Curr Opin Gastroenterol       Date:  2007-07       Impact factor: 3.287

2.  Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production.

Authors:  Elisabetta Volpe; Maxime Touzot; Nicolas Servant; Marie-Annick Marloie-Provost; Philippe Hupé; Emmanuel Barillot; Vassili Soumelis
Journal:  Blood       Date:  2009-08-24       Impact factor: 22.113

3.  Translating inflammatory bowel disease research into clinical medicine.

Authors:  Markus F Neurath; Susetta Finotto
Journal:  Immunity       Date:  2009-09-18       Impact factor: 31.745

Review 4.  Interactions between the host innate immune system and microbes in inflammatory bowel disease.

Authors:  Clara Abraham; Ruslan Medzhitov
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

Review 5.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

6.  Interleukin-33 exacerbates acute colitis via interleukin-4 in mice.

Authors:  Peter N Pushparaj; Dong Li; Mousa Komai-Koma; Rodrigo Guabiraba; James Alexander; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 7.  The Th17 family: flexibility follows function.

Authors:  Rajatava Basu; Robin D Hatton; Casey T Weaver
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

8.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Authors:  S Kugathasan; L J Saubermann; L Smith; D Kou; J Itoh; D G Binion; A D Levine; R S Blumberg; C Fiocchi
Journal:  Gut       Date:  2007-08-06       Impact factor: 23.059

9.  Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation.

Authors:  Lisa A Mielke; Sarah A Jones; Mathilde Raverdeau; Rowan Higgs; Anna Stefanska; Joanna R Groom; Alicja Misiak; Lara S Dungan; Caroline E Sutton; Gundula Streubel; Adrian P Bracken; Kingston H G Mills
Journal:  J Exp Med       Date:  2013-05-20       Impact factor: 14.307

10.  The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells.

Authors:  F Meylan; E T Hawley; L Barron; J L Barlow; P Penumetcha; M Pelletier; G Sciumè; A C Richard; E T Hayes; J Gomez-Rodriguez; X Chen; W E Paul; T A Wynn; A N J McKenzie; R M Siegel
Journal:  Mucosal Immunol       Date:  2013-12-25       Impact factor: 7.313

View more
  19 in total

Review 1.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

Review 2.  Inflammation and HIV Transmission in Sub-Saharan Africa.

Authors:  Rupert Kaul; Jessica Prodger; Vineet Joag; Brett Shannon; Sergey Yegorov; Ronald Galiwango; Lyle McKinnon
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

3.  Highly Human Immunodeficiency Virus-Exposed Seronegative Men Have Lower Mucosal Innate Immune Reactivity.

Authors:  Jennifer A Fulcher; Laura Romas; Jennifer C Hoffman; Julie Elliott; Terry Saunders; Adam D Burgener; Peter A Anton; Otto O Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-19       Impact factor: 2.205

4.  NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elena Bruni; Alessandra Roberto; Federico S Colombo; Anna Villa; Marita Bosticardo; Ileana Bortolomai; Elena Lo Presti; Serena Meraviglia; Francesco Dieli; Stefania Vetrano; Silvio Danese; Silvia Della Bella; Michele M Carvello; Matteo Sacchi; Giovanni Cugini; Giovanni Colombo; Marco Klinger; Paola Spaggiari; Massimo Roncalli; Immo Prinz; Sarina Ravens; Biagio di Lorenzo; Emanuela Marcenaro; Bruno Silva-Santos; Antonino Spinelli; Domenico Mavilio
Journal:  JCI Insight       Date:  2019-12-19

5.  IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer.

Authors:  Elena Voronov; Ron N Apte
Journal:  Cancer Microenviron       Date:  2015-12-19

6.  Distinct Effects of the Cervicovaginal Microbiota and Herpes Simplex Type 2 Infection on Female Genital Tract Immunology.

Authors:  B Shannon; P Gajer; T J Yi; B Ma; M S Humphrys; J Thomas-Pavanel; L Chieza; P Janakiram; M Saunders; W Tharao; S Huibner; K Shahabi; J Ravel; R Kaul
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

7.  Bowel Perforation During Haemophagocytic Lymphohistiocytosis Treatment with Corticosteroids and Anakinra.

Authors:  Jan Adamski; Björn Jäschke; Tuomas Nieminen; Wojciech Weigl
Journal:  Eur J Case Rep Intern Med       Date:  2021-10-12

8.  The Typhoid Toxin Promotes Host Survival and the Establishment of a Persistent Asymptomatic Infection.

Authors:  Lisa Del Bel Belluz; Riccardo Guidi; Ioannis S Pateras; Laura Levi; Boris Mihaljevic; Syed Fazle Rouf; Marie Wrande; Marco Candela; Silvia Turroni; Claudia Nastasi; Clarissa Consolandi; Clelia Peano; Toma Tebaldi; Gabriella Viero; Vassilis G Gorgoulis; Thorbjørn Krejsgaard; Mikael Rhen; Teresa Frisan
Journal:  PLoS Pathog       Date:  2016-04-07       Impact factor: 6.823

9.  Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial.

Authors:  Charilaos Triantafyllou; Maria Nikolaou; Ignatios Ikonomidis; Giorgos Bamias; Dimitrios Kouretas; Ioanna Andreadou; Maria Tsoumani; John Thymis; Ioannis Papaconstantinou
Journal:  Diagnostics (Basel)       Date:  2021-05-30

10.  Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease.

Authors:  Mohammad Salem; Ole Haagen Nielsen; Kris Nys; Shiva Yazdanyar; Jakob Benedict Seidelin
Journal:  Clin Transl Gastroenterol       Date:  2015-11-05       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.